Better Health for All

ANI Pharmaceuticals' core business focuses on developing, manufacturing, and commercializing therapeutics for rare diseases and chronic autoimmune disorders, including FDA-approved Cortrophin Gel for multiple indications, with a mission to 'Serving Patients, Improving Lives'.

The company has no evidenced revenue from products with negative health outcomes. ANI Pharmaceuticals offers patient support programs, including financial assistance like copay cards for commercially insured patients, potentially reducing costs to $0 per prescription fill, with a maximum annual assistance of $25,000. A Patient Assistance Program is available for those with limited or no insurance who meet financial requirements. The company invests a high single-digit percentage of Generics revenue into R&D and made a significant investment over the past five years in manufacturing processes and a U.S.-based supply chain for Cortrophin Gel. ANI Pharmaceuticals conducts a Phase 4 clinical trial for Cortrophin Gel to generate further scientific evidence. The company provides comprehensive risk disclosures for Cortrophin Gel, detailing contraindications, warnings, precautions, and adverse reactions. ANI Pharmaceuticals has a dedicated Nurse Access Specialist to help patients navigate treatment and offers in-person injection training at no cost. The company provides educational information through its 'Cortrophin In Your Corner' program, including injection guides and training videos. ANI Pharmaceuticals has established procedures for handling complaints regarding accounting, internal accounting controls, or auditing matters, with confidential and anonymous reporting mechanisms. The company prohibits retaliation against those who report in good faith.

Fair Pay & Worker Respect

The CEO-to-median employee pay ratio for fiscal year 2024 was 107:1, with CEO Nikhil Lalwani's total compensation at $8,841,402 and median employee pay at $82,949.

The company was served with grand jury subpoenas on or about September 20, 2017, relating to a federal investigation of the generic pharmaceutical industry. Additionally, a lawsuit was filed on September 11, 2013, alleging the company caused Louisiana's Medicaid agency to provide reimbursement for unapproved drug products.

Honest & Fair Business

No specific, concrete evidence was found in the provided article to assess ANI Pharmaceuticals, Inc. against any of the 'Honest & Fair Business' KPIs.

The article lists governance documents but contains no quantitative data regarding regulatory fines, transparency indices, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board independence, anti-corruption policies, or third-party verification.

Kind to Animals

No specific quantitative data is available to assess ANI Pharmaceuticals, Inc. against the 'Kind to Animals' ethical value. While preclinical data for Purified Cortrophin® Gel involved a mouse model,

this information does not provide the necessary quantitative metrics for any of the KPIs, such as the percentage of cruelty-free certified products, the extent of non-animal testing methods, the volume of animals used in testing annually, or the percentage of animal-derived ingredients replaced with ethical alternatives. Similarly, there is no evidence regarding humane certifications for operations, wildlife conservation impact, supplier audits, cage-free sourcing, animal testing policy details, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaborations, or public policy engagement on animal welfare.

Planet-Friendly Business

ANI Pharmaceuticals, Inc. reported total Scope 1, 2, and 3 greenhouse gas emissions of 42,500 metric tons CO2e in its 2022 sustainability report.

In the same year, 12.6% of its operational energy consumption was sourced from renewables. The company achieved a waste diversion rate of 78% in 2022.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points to assess ANI Pharmaceuticals, Inc. against the ethical value of Respect for Cultures & Communities. Information regarding formal partnerships with community groups, reinvestment in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion is not available.

Several articles explicitly state a lack of data for these specific metrics.

Safe & Smart Tech

No specific, scorable evidence was found across the provided articles for any of the Safe & Smart Tech KPIs. The articles primarily contain financial performance data and high-level descriptions of general cybersecurity policies without quantitative metrics or specific details required for assessment against the rubric's thresholds.

For example, while a cybersecurity program, external consultants, employee training, and an incident response plan are mentioned, there are no concrete metrics on their effectiveness, investment levels, or outcomes to align with the scoring rubric.